Same dose
Clinical trials such as the STEP programme (semaglutide) and SUSTAIN studies show that: Initial weeks : Modest weight loss primarily from reduced caloric intake Months 23 : More noticeable reduction becomes evident Months 36 : Continued steady weight loss as dose escalates Months 612 : Peak weight loss approaches, with most studies showing maximal effect by 1218 months It is important to recognise that GLP-1 medications require dose titration starting at a low dose and gradually increasing over several weeks according to the specific product's SmPC

DESCRIPTION TABLE OF CONTENTS METHODOLOGY DOWNLOAD PDF GLP-1 Agonists Market by Product (Ozempic, Wegovy, Mounjaro), Molecule (semaglutide, tirzepatide), Type (Patented, Biosimilars), Format (Single dose, Multi-dose, Tablets), ROA (SC, Oral), Indication (Diabetes, Obesity) - Global Forecast to 2033 USD 170.75 BN MARKET SIZE, 2033 OVERVIEW Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis The global GLP-1 agonists market is expected to reach USD 170.75 billion in 2033 from USD 64.42 billion in 2025 at a CAGR of 13.0% during the forecast period
The Dehydrating Effects of Caffeine and Alcohol: What You Need to Know
Longer treatment courses and maintenance dosing are generally appropriate for PCOS patients
Statins: absorption may be affected